Complement Therapeutics GmbH has raised €72 million in a Series A financing round to advance its portfolio of therapeutics for complement mediated diseases, initially focused on a gene therapy for the treatment of geographic atrophy. The Munich, Germany-based company is a spin-out of Manchester University, UK, and led by Rafiq Hasan, formerly head of ophthalmology at Bayer AG.
